Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285473 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Naltrexone For ME/CFS: Dose-Finding
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT07285473 is a Phase 2 study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 75 participants.
The verdict
NCT07285473, a Phase 2 study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.
Interventions
- DRUG Low-Dose Naltrexone, 1.5mg
- DRUG Low-Dose Naltrexone, 3.0mg
- DRUG Low-Dose Naltrexone, 4.5mg
- DRUG Low-Dose Naltrexone, 6.0mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2028-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07285473
The ClinicalTrials.gov registry entry for NCT07285473 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Low-Dose Naltrexone, 1.5mg is the first listed.
NCT07285473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07285473 about?
NCT07285473 is a clinical study titled "Low-Dose Naltrexone For ME/CFS: Dose-Finding". This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.
What is the current status of trial NCT07285473?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2026-09-01. Estimated completion is 2028-04-01.
What interventions are being tested in trial NCT07285473?
The interventions under investigation include: Low-Dose Naltrexone, 1.5mg (DRUG), Low-Dose Naltrexone, 3.0mg (DRUG), Low-Dose Naltrexone, 4.5mg (DRUG), Low-Dose Naltrexone, 6.0mg (DRUG).
Who is sponsoring clinical trial NCT07285473?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.